Summary of Kunming Pharmaceutical Group Conference Call Company Overview - **Company**: Kunming Pharmaceutical Group - **Year**: 2024 Key Financial Performance - **Revenue**: 8.4 billion yuan, a 9.07% increase compared to the previous audited year, remaining stable year-on-year [3] - **Net Profit**: 648 million yuan, a 19.86% year-on-year increase [3] - **Net Profit (Excluding Non-recurring Items)**: 419 million yuan, a 25% year-on-year increase, marking a historical high for the company [3] - **Sales Expense Ratio**: Decreased by 4.82 percentage points [3] - **Operating Cash Flow**: 808 million yuan [3] - **Return on Equity**: Increased by 0.97 percentage points year-on-year [3] Strategic Initiatives - **Focus on Aging Population**: The company is strategically positioned in the aging health sector, supported by Huazhong Sanjiu, aiming for high-quality development [4] - **Resource Integration**: Integration of Huazhong Sanjiu resources to optimize the Kunyang business system [4] - **Reform Projects**: Initiated the Lecheng reform project and completed the acquisition of Shenghuo [4] Product Performance - **Kun Traditional Medicine Division**: Achieved a 20% year-on-year growth in core products such as Jianpiwei Granules, Shugan Granules, and Qingfei Huatan Wan [5] - **Brand Collaboration**: Enhanced brand influence through collaboration with CCTV [5] - **Overseas Business**: Significant performance with products like Qinghao Suan Zhi Pi Kuan Pian receiving international certification and global fund orders [7] Market Expansion and Sales Strategy - **Sales Growth Target**: Aiming for over 10% growth in sales of Xuesaitong oral products in 2025, utilizing a 4C model for targeted marketing [8][9] - **Brand Building**: Focus on building the 777 brand to address chronic disease management for the elderly [18] - **Sales and Pricing Strategy**: Plans to optimize sales and pricing strategies based on patient demographics and healthcare service accessibility [25] Challenges and Responses - **Impact of Centralized Procurement**: The company is adapting to the challenges posed by centralized procurement policies, which have increased competition [13] - **Frozen Powder Products**: Facing a decline in sales due to centralized procurement policies, the company is exploring new market opportunities [16] Future Outlook - **Long-term Goals**: Aiming to become a significant player in the scientific field in China and establish a global brand image for Kunming Pharmaceutical over the next decade [28] - **Strategic Execution**: Implementing a three-year plan to ensure strategic goals are met, focusing on employee motivation and organizational transformation [29] Additional Insights - **Cultural and Academic Development**: Emphasizing the importance of academic and cultural construction to enhance brand influence and market presence [10] - **Inventory Management**: Addressing inventory pressures through strategic brand building and academic promotion [24] This summary encapsulates the key points from the conference call, highlighting the company's financial performance, strategic initiatives, product performance, market expansion strategies, challenges, and future outlook.

Investment Rating - The report does not specify a clear investment rating for the company, but it suggests maintaining attention to the stock due to its strong brand competitiveness and stable growth in main business [7]. Core Views - The company achieved a revenue of 84.0 billion yuan in 2024, with a year-on-year growth rate of 9.07% [2][7]. - The net profit attributable to the parent company was 6.5 billion yuan, reflecting a year-on-year increase of 45.74% [2][7]. - The acquisition of a 51% stake in China Resources Shenghuo in December 2024 significantly enhanced the company's performance, resolving competition issues with its core product [7]. - The company aims to double its revenue by the end of 2028, targeting an industrial revenue of 10 billion yuan [7]. Financial Performance Summary - **Revenue Forecast**: Expected revenues for 2025, 2026, and 2027 are 87.3 billion yuan, 94.7 billion yuan, and 103.6 billion yuan, respectively, with growth rates of 4%, 9%, and 9% [8]. - **Net Profit Forecast**: Projected net profits for 2025, 2026, and 2027 are 7.3 billion yuan, 8.8 billion yuan, and 10.6 billion yuan, corresponding to PE ratios of 18, 15, and 13 [7][10]. - **Earnings Per Share (EPS)**: EPS is expected to increase from 0.86 yuan in 2024 to 1.39 yuan by 2027 [2][10]. - **Return on Equity (ROE)**: ROE is projected to rise from 11.14% in 2024 to 12.79% in 2027 [2][10]. Business Segment Analysis - **Oral Pharmaceuticals**: Revenue from oral pharmaceuticals is expected to grow from 36.9 billion yuan in 2024 to 56.2 billion yuan by 2027, with a consistent growth rate of 15% [8]. - **Injectable Pharmaceuticals**: Revenue from injectable pharmaceuticals is projected to remain stable, with a slight increase from 5.4 billion yuan in 2024 to 6.2 billion yuan by 2027 [8]. - **Wholesale and Retail**: Revenue from drug wholesale and retail is expected to grow modestly from 36.6 billion yuan in 2024 to 40.3 billion yuan by 2027 [8]. Strategic Initiatives - The company is focusing on enhancing its brand value and channel distribution, particularly through partnerships with China Resources [7]. - Continuous investment in R&D, with 1.4 billion yuan allocated in 2024, aims to drive product innovation and improve treatment options for chronic diseases [7].

Investment Rating - The report suggests maintaining attention on Kunming Pharmaceutical Group with a target price not specified for the next six months [1]. Core Views - The acquisition of 51% stake in China Resources Sanjiu has significantly enhanced Kunming Pharmaceutical's performance, resolving competition issues and boosting sales of its core product, Xuesaitong soft capsules, which saw an 11.27% year-on-year increase [7]. - The company aims to double its revenue by the end of 2028, targeting 10 billion yuan in industrial revenue, driven by a strategic focus on the aging population and chronic disease treatment [7]. - The report highlights strong growth in Kunming Traditional Chinese Medicine, with a revenue of 809 million yuan and a profit margin of 16% in 2024, supported by enhanced channel strategies and brand value [7]. Financial Summary - For 2024, the company reported a revenue of 8.401 billion yuan, with a year-on-year growth rate of 9.07%. The net profit attributable to the parent company was 648.08 million yuan, reflecting a growth rate of 45.74% [2][10]. - The earnings per share (EPS) for 2024 is projected at 0.86 yuan, with a return on equity (ROE) of 11.14% [2][10]. - The forecast for net profit for 2025-2027 is 731.76 million yuan, 884.02 million yuan, and 1.055 billion yuan, respectively, with corresponding price-to-earnings (PE) ratios of 18, 15, and 13 [7][10]. Revenue and Growth Projections - The projected revenue for 2025 is 8.727 billion yuan, with a growth rate of 3.87%, and for 2026, it is expected to reach 9.473 billion yuan, growing by 8.55% [2][10]. - The report anticipates a continuous increase in sales volume for Xuesaitong soft capsules, with expected growth rates of 15% for the years 2025-2027 [8]. Strategic Initiatives - The company is focusing on enhancing its product pipeline through R&D investments, with 140 million yuan allocated in 2024, leading to the approval of new drugs for chronic diseases [7]. - The integration with China Resources is expected to further strengthen the company's market position and operational efficiency [7].

[ T able_StockInfo] 2025 年 03 月 12 日 证券研究报告•2024 年年报点评 当前价：17.77 元 昆药集团（600422）医药生物 目标价：——元（6 个月） 并表圣火开启协同，昆中药提质增效显著 | [Table_MainProfit] 指标/年度 | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业收入（百万元） | 8401.45 | 8726.76 | 9472.63 | 10356.33 | | 增长率 | 9.07% | 3.87% | 8.55% | 9.33% | | 归属母公司净利润（百万元） | 648.08 | 731.76 | 884.02 | 1055.24 | | 增长率 | 45.74% | 12.91% | 20.81% | 19.37% | | 每股收益 EPS（元） | 0.86 | 0.97 | 1.17 | 1.39 | | 净资产收益率 ROE | 11.14% | 10.60% | 11.77% | 12.79% | | PE | 21 | 1 ...

Investment Rating - The report maintains a "Buy" rating for Kunming Pharmaceutical Group [2] Core Views - The company achieved a revenue of 8.401 billion yuan in 2024, a slight decrease of 0.34% year-on-year, while net profit attributable to shareholders increased by 19.86% to 648 million yuan [6] - The acquisition of Huaren Shenghuo is expected to enhance profitability and support the strategic integration of the company's Sanqi business [6] - The stable landing of centralized procurement is anticipated to lead to a recovery in product prices, providing a favorable outlook for future earnings [6] Financial Performance - In Q4 2024, the company reported a revenue of 2.601 billion yuan and a net profit of 203 million yuan [6] - The company plans to distribute a dividend of 3 yuan per ten shares, resulting in a payout ratio of 35.04% [6] - The company’s core products, including "Kun Traditional Chinese Medicine 1381," have shown significant growth, with combined revenue from key products increasing by 20% [6] Strategic Developments - The integration of Huaren Shenghuo into the company’s financials is expected to bolster profits and establish a benchmark in the Sanqi industry chain [6] - The company is focusing on brand building and channel development, which are progressing steadily [6] - The centralized procurement renewal in December 2024 has stabilized prices for key products, ensuring a stable revenue stream until December 31, 2027 [6] Earnings Forecast - The projected profits for 2025, 2026, and 2027 are estimated at 750 million yuan, 910 million yuan, and 1.135 billion yuan respectively [6] - The price-to-earnings ratio (PE) is expected to be 18, 15, and 12 times for the years 2025, 2026, and 2027 respectively [6]

医药生物/中药Ⅱ 昆药集团（600422.SH） 三七产业布局逐步优化， "创新+出海"赋能未来成长 2025 年 03 月 12 日 投资评级：买入（维持） | 日期 | 2025/3/11 | | --- | --- | | 当前股价(元) | 17.77 | | 一年最高最低(元) | 24.11/11.92 | | 总市值(亿元) | 134.51 | | 流通市值(亿元) | 134.51 | | 总股本(亿股) | 7.57 | | 流通股本(亿股) | 7.57 | | 近 3 个月换手率(%) | 99.96 | 股价走势图 -60% -40% -20% 0% 20% 40% 2024-03 2024-07 2024-11 昆药集团 沪深300 数据来源：聚源 相关研究报告 《2024 年利润超预期增长，2025 年轻 装上阵稳步向前 —公司信息更新报 告》-2025.2.11 《Q3 单季度营收利润环比向上，融合 变革深入推进—公司信息更新报告》 -2024.10.28 《2024H1 营收小幅承压，品牌建设工 作稳步推进—公司信息更新报告》 -2024.8.24 | 余汝意（分析师） | ...

Investment Rating - The report maintains a "Buy" rating for Kunming Pharmaceutical Group [2][6] Core Views - In 2024, the company achieved revenue of 8.401 billion yuan (down 0.34% year-on-year) and a net profit attributable to shareholders of 648 million yuan (up 19.86%) [6] - The acquisition of Huaren Shenghuo is expected to enhance profitability and support the strategic integration of the company's product lines [6] - The stable landing of centralized procurement is anticipated to lead to a recovery in the company's product prices [6] Financial Performance - Revenue and profit forecasts for 2025-2027 are projected at 9.301 billion yuan, 10.102 billion yuan, and 11.041 billion yuan respectively, with net profits of 747 million yuan, 912 million yuan, and 1.135 billion yuan [9] - The company plans to distribute a dividend of 3 yuan per ten shares, resulting in a payout ratio of 35.04% [6] - The gross profit margin is expected to improve from 43.5% in 2024 to 48.2% by 2027 [9] Market Position and Strategy - The company is focusing on brand building and channel development, with significant growth in key products such as "Kunchinese Medicine 1381" and "Shu Gan Granules" [6] - The integration of Huaren Shenghuo is expected to create a benchmark enterprise in the Sanqi industry chain [6] - The company has successfully maintained stable prices for its products under the centralized procurement policy, which is set to last until December 31, 2027 [6]

医药生物/中药Ⅱ 昆药集团（600422.SH） 三七产业布局逐步优化， "创新+出海"赋能未来成长 2025 年 03 月 12 日 投资评级：买入（维持） | 日期 | 2025/3/11 | | --- | --- | | 当前股价(元) | 17.77 | | 一年最高最低(元) | 24.11/11.92 | | 总市值(亿元) | 134.51 | | 流通市值(亿元) | 134.51 | | 总股本(亿股) | 7.57 | | 流通股本(亿股) | 7.57 | | 近 3 个月换手率(%) | 99.96 | 股价走势图 -60% -40% -20% 0% 20% 40% 2024-03 2024-07 2024-11 昆药集团 沪深300 数据来源：聚源 相关研究报告 《2024 年利润超预期增长，2025 年轻 装上阵稳步向前 —公司信息更新报 告》-2025.2.11 《Q3 单季度营收利润环比向上，融合 变革深入推进—公司信息更新报告》 -2024.10.28 《2024H1 营收小幅承压，品牌建设工 作稳步推进—公司信息更新报告》 -2024.8.24 | 余汝意（分析师） | ...

医药生物/中药Ⅱ 昆药集团（600422.SH） 三七产业布局逐步优化， "创新+出海"赋能未来成长 2025 年 03 月 12 日 投资评级：买入（维持） 相关研究报告 《2024 年利润超预期增长，2025 年轻 装上阵稳步向前 —公司信息更新报 告》-2025.2.11 《Q3 单季度营收利润环比向上，融合 变革深入推进—公司信息更新报告》 -2024.10.28 《2024H1 营收小幅承压，品牌建设工 作稳步推进—公司信息更新报告》 -2024.8.24 | 余汝意（分析师） | 巢舒然（联系人） | | --- | --- | | yuruyi@kysec.cn | chaoshuran@kysec.cn | | 证书编号：S0790523070002 | 证书编号：S0790123110015 | 2024 年收购华润圣火 51%股权事项落地，血塞通软胶囊品牌优势进一步加强 2025 年 3 月 12 日，公司公告 2024 年度报告，2024 年实现营收 84.01 亿元（重 述调整前同比+9.07%，重述调整后同比-0.34%，下文皆为同比口径）；归母净利 润 6.48 亿元（重述调整前+ ...

Investment Rating - The report assigns an "Accumulate" rating to the company [1] Core Views - The company is expected to embrace centralized procurement policies actively, which will enhance its medical terminal coverage and drive future business development [2][4] - The company reported a stable performance in its oral medication segment, while the injection segment experienced a significant decline [3] - The construction of the Kun Pharmaceutical business model is showing significant results in channel reform, which is expected to improve product accessibility and market coverage [5][6] Financial Performance Summary - In 2024, the company achieved a total revenue of 8.401 billion yuan, which is essentially flat year-on-year, and a net profit attributable to shareholders of 648 million yuan, reflecting a year-on-year growth of 19.86% [2] - The company’s oral medication revenue reached 3.693 billion yuan in 2024, marking an 8.15% increase year-on-year, while the injection segment revenue fell by 49.09% to 539 million yuan [3] - The company anticipates a double-digit revenue growth in 2025, with projected revenues of 9.3 billion yuan and a net profit of 757 million yuan [8] Business Segment Analysis - The blood clotting series products showed robust growth, with the sales volume of blood clotting soft capsules increasing by 11.27% to 1.584 billion capsules in 2024 [3] - The company’s wholesale and retail business generated 3.655 billion yuan in revenue, reflecting a 6.07% year-on-year increase [3] - The company is focusing on enhancing its distribution channels through the Kun Pharmaceutical business model, which aims to improve the coverage of core products in retail terminals [5][6]